Faculty Profiles - OHTAKE Tohru

Papers - OHTAKE Tohru

Division display1 - 20 of about 144／ All the affair displays >>

A qualitative study on the impacts of the 2011 triple disaster earthquake on breast cancer patients diagnosed post-disaster

Nashimoto M, Kaneda Y, Ozaki A, Hara A, Sawano T, Saito H, Murakami M, Kotera Y, Gonda K, Wada M, Tachibana K, Ohtake T, Ohira H, Tsubokura M

SOCIAL ISSUES 3 ( 3 ) 5 - 19 2025.9

A comparative analysis of digital mammography and digital breast tomosynthesis in Japanese women

Hara A, Ozaki A, Wada M, Gonda K, Hagiwara A, Shirato M, Kariya N, Yasui A, Omori R, Nashimoto M, Sawano T, Kurokawa T, Tachibana K, Ohtake T, Shimmura H, Uematsu T

Cureus 2025.7

Online general exercise management program for patients with breast cancer-related lymphoedema: a protocol for a pilot randomised controlled trial International coauthorship

Arinaga Y, Sato F, Miyata S, Piller N and Ohtake T

Journal of Lymphoedema 20 70 - 73 2025.3

Germline pathogenic variants and clinical outcomes in Asian patients with breast cancer

Kitadai R, Yazaki S, Kuchiba A, Yamanaka T, Shiino, S, Yamauchi C, Harano K, Saito M, Hirotsu Y, Aiba H, Yoshida Y, Hamamoto R, Shimizu C, Shimomura A, Kojima Y, Shimoi T, Momozawa Y, Sudo K, Yoshida M, Sunami K, Hori M, Katanoda K, Shimada Y, Yamashita Y, Kogawa T, Murata T, Fujiwara S, Miyagi Y, Nakagomi H, Tachibana K, Omata M, Ohtake T, Suto A, Onishi T, Naito Y, Yamashita T, Yonemori K,. Kohno T, Shiraishi K

Cancer Science 2025.2

Breast cancer screening rates and influencing factors among LGBTQ groups in Japan

Hara A, Ozaki A, Murakami M, Saito H, Nashimoto M, Hori D, Tsubokura M, Gonda K, Wada M, Tachibana K, Ohtake T, Tabuchi T

Breast Cancer 2025.2

Development of cancer therapy‑related cardiac dysfunction in anthracycline‑treated breast cancer patients: a retrospective study

Kuroda J, Oikawa M, Tokuda E, Tachibana K, Sasaki E, Ohtake T, Takeishi Y, Saji S

Support Care Cancer 2024.12

Fukushima outpatient pharmacotherapy model for breast cancer

Ozaki A, Azami A, Azami Y, Sugeno T, Yasui A, Gonda K, Tanimoto T, Tachibana K, Ohtake T

JMA Journal 7 ( 4 ) 618 - 621 2024.10

Impact of large-scale disasters on the breast care: A qualitative analysis of patient experiences during the 2011 triple disaster in Fukushima, Japan

Kaneda Y, Ozaki A, Murakami M, Saito H, Sawano T, Yamashita E, Gonda K, Tachibana K, Ohtake T, Tsubokura M, Ohira H

International Journal of Disaster Risk Reduction ( 109 ) 104582 2024.5

Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open‐label, nonrandomized, phase 1 study

Naoki K, Igawa S, Uojima H, Tsumura H, Sengoku N, Karayama M, Shimomura A, Ohtake T, Shio Y, Hosokawa A, Komatsu Y, Kumagai Y

Cancer 130 3745 - 3756 2024.5

Endosomal protein expression of γ1‑adaptin is associated with tumor growth activity and relapse‑free survival in breast cancer

Hoshi N, Uemura T, Tachibana K, Abe S, Murakami-Nishimagi Y, Okano M, Noda M, Saito K, Kono K, Ohtake T, Waguri S

Breast Cancer 31 ( 2 ) 305 - 316 2024.1

Long-term experience on breast cancer-related lymphedema in the coastal area of Fukushima, Japan after the 2011 triple disaster

Kobayashi N, Ozaki A, Kotera Y, Kaneda Y, Bhandari D, Takamatsu K, Kasai T, Arai M, Takasaki J, Saito H, Sawano T, Kanemoto Y, Sato H, Tsubokura M, Kurokawa T, Tachibana K, Wada M, Tanimoto T, Ohtake T, Ejiri T, Shimmura H and Kanzaki N

in Vivo 38 272 - 280 2024.1

The necessity of proactive measures from healthcare providers highlighted by delayed breast cancer diagnosis due to COVID- 19: A case report

Kaneda Y, Ozaki A, Namba M, Sawano T, Wada M, Saito H, Kanemoto Y, Kurokawa T, Tsubokura M, Tachibana K, Tanimoto T, Ohtake T, Ejiri T, Shimmura H, Kanzaki N

Clin Case Rep 2023.9

Claudin-4-adhesion signaling drives breast cancer metabolism and progression via liver X receptor β

Murakami-Nishimagi Y, Sugimoto K, Kobayashi M, Tachibana K, Kojima M, Okano M, Hashimoto Y, Saji S, Ohtake T, Chiba H

Breast Cancer Research 2023.4

E3 ubiquitin ligase NEDD4 affects estrogen receptor expression and the prognosis of patients with hormone receptor-positive breast cancer

Natori N, Suga J, Tokuda E, Tachibana K, Imai J, Honma R, Azami Y, Noda M, Sasaki E, Watanabe S, Ohtake T and Saji S

Cancers 15 ( 539 ) 2023.1

Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial

Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M

Lancet Oncology 23 ( 5 ) 636 - 649 2022.4

Evaluation of a new combination product with novel medical device for pegfilgrastim administration.

Aruga T, Doihara H, Yanagita Y, Ishida T, Yamashita T, Uehara K, Taira T, Tsurutani J, Takeshita T, Tsuyuki S, Kaneko K, Ohtake T, Yamaguchi Y, Hara Y, Saji S

Cancer Science 2022.3

Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan".

Ozaki A, Tachibana K, Ohtake T

Breast cancer (Tokyo, Japan) 29 ( 1 ) 191 2022.1（ ISSN:1340-6868 ）

Octogenarians’ breast cancer is associated with an unfavorable tumor immune microenvironment and worse　disease-free survival

Okano M, Oshi M, Mukhopadhyay S, Qi Q, Yan L, Endo I, Ohtake T and Takabe K

Cancers 2021.6

Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to “A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Tohoku region in Japan”

Ozaki A, Tachibana K, Ohtake T

Breast Cancer 2021.4

A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer

Kurebayashi J, Shiba E, Toyama T, Matsumoto H, Okazaki M, Nomizu T, Ohtake T, Fujii T, Ohashi Y

Breast Cancer 2021.3

　PREV- NEXT 　

<OHTAKE Tohru>

Papers - OHTAKE Tohru